Patel Nirav C, Hemli Jonathan M, Seetharam Karthik, Singh Varinder P, Scheinerman S Jacob, Pirelli Luigi, Brinster Derek R, Kim Michael C
Department of Cardiovascular & Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York, NY.
Department of Cardiovascular & Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York, NY.
J Thorac Cardiovasc Surg. 2022 May;163(5):1839-1846.e1. doi: 10.1016/j.jtcvs.2020.04.171. Epub 2020 May 29.
Debate continues as to the optimal minimally invasive treatment modality for complex disease of the left anterior descending coronary artery, with advocates for both robotic-assisted minimally invasive direct coronary artery bypass and percutaneous coronary intervention with a drug-eluting stent. We analyzed the midterm outcomes of patients with isolated left anterior descending disease, revascularized by minimally invasive direct coronary artery bypass or drug-eluting stent percutaneous coronary intervention, focusing on those with complex lesion anatomy.
A retrospective review was undertaken of all patients who underwent coronary revascularization between January 2008 and December 2016. From this population, 158 propensity-matched pairs of patients were generated from 158 individuals who underwent minimally invasive direct coronary artery bypass for isolated complex left anterior descending disease and from 373 patients who underwent percutaneous coronary intervention using a second-generation drug-eluting stent. Midterm survival and incidence of repeat left anterior descending intervention were analyzed for both patient groups.
Overall 9-year survival was not significantly different between patient groups both before and after propensity matching. Midterm mortality in the matched minimally invasive direct coronary artery bypass group was low, irrespective of patient risk profile. By contrast, advanced age (hazard ratio, 1.10; P = .012) and obesity (hazard ratio, 1.09; P = .044) predicted increased late death after drug-eluting stent percutaneous coronary intervention among matched patients. Patients who underwent minimally invasive direct coronary artery bypass were significantly less likely to require repeat left anterior descending revascularization than those who had percutaneous coronary intervention, both before and after propensity matching. Smaller stent diameter in drug-eluting stent percutaneous coronary intervention was associated with increased left anterior descending reintervention (hazard ratio, 3.53; P = .005).
In patients with complex disease of the left anterior descending artery, both minimally invasive direct coronary artery bypass and percutaneous coronary intervention are associated with similar excellent intermediate-term survival, although reintervention requirements are lower after surgery.
对于左前降支冠状动脉复杂疾病的最佳微创治疗方式仍存在争议,机器人辅助微创直接冠状动脉旁路移植术和药物洗脱支架经皮冠状动脉介入治疗均有支持者。我们分析了孤立性左前降支疾病患者通过微创直接冠状动脉旁路移植术或药物洗脱支架经皮冠状动脉介入治疗实现血运重建后的中期结果,重点关注病变解剖结构复杂的患者。
对2008年1月至2016年12月期间接受冠状动脉血运重建的所有患者进行回顾性研究。从该人群中,从158例因孤立性复杂左前降支疾病接受微创直接冠状动脉旁路移植术的患者和373例使用第二代药物洗脱支架进行经皮冠状动脉介入治疗的患者中生成了158对倾向匹配的患者。分析了两组患者的中期生存率和再次左前降支介入治疗的发生率。
倾向匹配前后,两组患者的总体9年生存率无显著差异。匹配的微创直接冠状动脉旁路移植术组的中期死亡率较低,与患者风险特征无关。相比之下,高龄(风险比,1.10;P = .012)和肥胖(风险比,1.09;P = .044)预示着匹配患者在药物洗脱支架经皮冠状动脉介入治疗后晚期死亡增加。在倾向匹配前后,接受微创直接冠状动脉旁路移植术的患者比接受经皮冠状动脉介入治疗的患者再次进行左前降支血运重建的可能性显著降低。药物洗脱支架经皮冠状动脉介入治疗中较小的支架直径与左前降支再次介入治疗增加相关(风险比,3.53;P = .005)。
在左前降支动脉复杂疾病患者中,微创直接冠状动脉旁路移植术和经皮冠状动脉介入治疗均与相似的优异中期生存率相关,尽管手术后再次介入治疗的需求较低。